Pharmaceuticals News and Research

RSS

Obstetricians/gynecologists rank Pfizer as No. 1 pharmaceutical company: SDI

According to SDI's Pharmaceutical Company Image 2011 study, obstetricians/gynecologists ranked Pfizer No. 1 overall. Forty percent of the 325 participating OB/GYNs reported that Pfizer was one of the three companies they held in highest esteem. In the 2010 study, Pfizer placed second.

30 Jun 2011

Drug companies collaborate with DNDi support to develop drug for African sleeping sickness

Researchers from Scynexis Inc. of Research Triangle Park, N.C., and Anacor Pharmaceuticals in Palo Alto, Calif., sponsored by the Drugs for Neglected Diseases initiative, on Tuesday reported in the journal PLoS Neglected Tropical Diseases that a new experimental drug kills the parasite that causes African sleeping sickness in mice and will enter human clinical trials this year, ScienceNOW reports.

30 Jun 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries

SciDev.Net reports on the 7th World Conference of Science Journalists, taking place this week in Qatar, where participants discussed how the number of clinical trials in developing countries is surging despite legal and ethical frameworks often not being in place.

30 Jun 2011

Prevalence rate of Parkinson's is higher than previously thought

Parkinson's Disease, brought to public awareness by figures such as Michael J. Fox, is not just difficult to diagnose. It's also difficult to accurately estimate how many people actually suffer from the disease. Current statistics come from small-scale studies, usually based on information from hospital clinics, and no registries or formal databases exist to track how many people have the disease.

30 Jun 2011

Provectus presents additional data on PV-10 at two separate melanoma conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

30 Jun 2011

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

The budget is not realistic, counting on fantastical revenue projections as well as a redevelopment gambit that's likely to be blocked in court. It makes deep cuts in state programs that will have unwelcome repercussions in years to come. And if the revenue projections prove to be as overly optimistic as they seem, there will be more damaging cuts to education, child care and health services. Nevertheless, it's a more earnest effort to clean up the state's budget mess than Sacramento has seen in a decade or more.

30 Jun 2011

Supreme Court rules in favor of ‘pharma’ data mining

The U.S. Supreme Court ruled that the pharmaceutical companies could use the information that they gained from doctors’ prescribing records. The data mining had been restricted in Maine following the high court ruling that struck down a similar law in Vermont.

29 Jun 2011

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

The Center of Innovation for Nanobiotechnology (COIN) has announced the upcoming NanoBio Executive Roundtable event to be hosted at The Hawthorne Inn in Winston-Salem, NC on July 14, 2011. This Roundtable will address a significant hurdle to nanobiotechnology development and commercialization—early-stage funding.

29 Jun 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States.

29 Jun 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

29 Jun 2011

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it has entered into definitive agreements with certain new and existing accredited investors providing for a private placement of common stock and warrants in which the Company will receive $24 million in gross proceeds.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that they acquired marketing and distribution rights to several unique branded products for the treatment of pain from Atley Pharmaceuticals. Some products are approved and some are pending approval with the Food and Drug Administration (FDA).

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Pharmaceuticals News and Research

Obstetricians/gynecologists rank Pfizer as No. 1 pharmaceutical company: SDI

Drug companies collaborate with DNDi support to develop drug for African sleeping sickness

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Conference examines lagging ethical guidelines in face of expanding clinical trials in developing countries

Prevalence rate of Parkinson's is higher than previously thought

Provectus presents additional data on PV-10 at two separate melanoma conferences

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

Supreme Court rules in favor of ‘pharma’ data mining

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

A.P. Pharma enters into definitive agreements for $24M private placement of common stock and warrants

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Amorfix fiscal 2011 net loss decreases to $3,330,437

Hi-Tech Pharmacal pays $3.6M for rights to Atley's branded pain treatment products

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

FDA clears Nuvo's IND for Lidocaine Spray formulation

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence